Scientists have recently developed a rapid and inexpensive drug-screening method to target diseases which have previously been problematic for drug manufacturers to aim for, it has been said.
According to researchers at the Whitehead Institute, the new technique uses baker's yeast in order to synthesise and screen molecules, in turn cutting down on target discovery and preliminary testing time to only a few weeks.
It is hoped that large collections of molecular compounds could be worked through this method, in turn developing faster study times when it comes to looking into Parkinson's disease and other neurodegenerative disorders.
Whitehead member and professor of biology at Massachusetts Institute of Technology Susan Lundquist said: "I think it's a very exciting method.
"It provides much greater diversity in the chemical compounds you can study because you can screen millions of compounds in the same go."
This month, Mayo Clinic researchers engineered the STructural Abnormality iNDex - or STAND-Map - to help in the diagnosis of a number of neurodegenerative disorders.
Please click here for advice to help you find the right type of care.